Product Press Release
Bio-Rad Announces CE Marking of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis Testing Method
HERCULES, Calif.—November 29, 2016—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced CE IVD marking for its BioPlex 2200 Syphilis Total & RPR assay, a novel universal testing method to aid in the diagnosis of syphilis infection.
The BioPlex 2200 Syphilis Total & RPR assay offers laboratories the first fully automated Treponemal/non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies and is capable of RPR titer determination for effective treatment monitoring. Compared to traditional manual RPR card tests, the automation of RPR offers labor savings, objective result reporting, and improved workflow to laboratories.
“The addition of the BioPlex 2200 Syphilis Total & RPR assay broadens our expanding BioPlex infectious disease menu while offering laboratories a simplified approach to syphilis testing and is adaptable to any syphilis testing algorithm used by the laboratory,“ said John Hertia, Bio-Rad President, Clinical Diagnostics Group.
The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in the growing infectious disease menu for the BioPlex 2200 system, a fully automated system utilizing multiplex technology. The BioPlex 2200 system provides clinical laboratories with the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.
Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com